Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: Report of the OPERA study

Gut

Volumn 67, Issue 10, 2018, Pages 1824-1835

  Sandborn, William J ^a   Lee, Scott D ^b   Tarabar, Dino ^c   Louis, Edouard ^d   Klopocka, Maria ^e   Klaus, Jochen ^f   Reinisch, Walter ^g,h   Hebuterne, Xavier ⁱ   Park, Dong II ^j   Schreiber, Stefan ^k   Nayak, Satyaprakash ^l   Ahmad, Alaa ^l   Banerjee, Anindita ^l   Brown, Lisa S ^l   Cataldi, Fabio ^l   Gorelick, Kenneth J ^l   Cheng, John B ^l   Hassan Zahraee, Mina ^l   Clare, Robert ^l   D'Haens, Geert R ^m  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Military Medical Academy   (Serbia)

^d UNIVERSITY OF LIÈGE   (Belgium)

^e NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^f UNIVERSITY HOSPITAL ULM   (Germany)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h MCMASTER UNIVERSITY   (Canada)

ⁱ UNIVERSITÉ CÔTE D'AZUR   (France)

^j School of Medicine   (South Korea)

^k UNIVERSITY OF KIEL   (Germany)

^l PFIZER INC   (United States)

^m ACADEMIC MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN; MONOCLONAL ANTIBODY; PF 00547659; PLACEBO; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; GASTROINTESTINAL AGENT; PF-00547659;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; COLONOSCOPY; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FECES LEVEL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; LACK OF DRUG EFFECT; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; VERY ELDERLY; CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MONITORING; METABOLISM; MIDDLE AGED; PATIENT ACUITY; PROCEDURES; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; C-REACTIVE PROTEIN; COLONOSCOPY; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG MONITORING; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; PATIENT ACUITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85048247474     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2016-313457     Document Type: Article

References (28)

1. Baumgart DC, Sandborn WJ, Crohn's disease. Lancet 2012;380:1590-605.
2. Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 2010; 139:1 147-55.
3. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am 1 Gastroenterol 2009;104:465-83.
4. Peyriri-Biroulet L, Deltenre P, de Suray N, etal. Efficacy and safety of tumor necrosis factor Antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin GastroenterolHepatol 2008;6:644-53.
5. Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. N EnglJ Med 2016;375:1946-60.
6. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N EnglJ Med 2013;369:711-21.
7. Sandborn WJ, Rutgeerts P, Enns R.et al .Adalimumab induction therapy for Crohn's disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007;146:829-38.
8. Streeter PR, Berg EL, Rouse BTN, et al. A tissue-specific endothelial cell molecule involved in lymphocyte homing. Nature 1988;331:41-6.
9. Nakache M, Berg EL, Streeter PR, et al. The mucosal vascular addressin is a tissue-specific endothelial cell adhesion molecule for circulating lymphocytes. Nature 1989;337:179-81.
10. Briskin M,Winsor-Hines D, Shyjan A, e tal. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997; 151:97-110.
11. Allavena R, Noy S,Andrews M, etal. CNS elevation of vascular and not mucosal addressin cell adhesion molecules in patients with multiple sclerosis. Am J Pathol 2010;176:556-62.
12. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N EnglJ Med Overseas Ed 2012;366:1870-80.
13. Colombel JF, Sands BE, Rutgeerts P, ef al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut 2016.
14. Pullen N, Molloy E, Carter D, etal. Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody. BrJ Pharmacol 2009;157:281-93.
15. Best WR, Becktel JM, Singleton JW, etal. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-44.
16. Daperno M, D'Haens G, VanAssche G, etal. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrolntest Endosc 2004;60:505-12.
17. Larbi A, FulopT. From 'truly naive' to 'exhausted senescent'T cells: when markers predict functionality. Cytometry PartA 2014;85:25-35.
18. Su C, Lichtenstein GR, Krok K, et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology 2004;126:1257-69.
19. Schreiber S, Rutgeerts P, Fedorak RN, etal. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005;129:807-18.
20. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007;132:1672-83.
21. Sandborn WJ, Schreiber S, Feagan BG, etal. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol 2011;9:670-8.
22. Colombel JF, Sandborn WJ, Reinisch W, etal. Infliximab, azathioprine, or combination therapy for Crohn's disease. N EnglI Med 2010;362:1383-95.
23. Sandborn WJ, Gasink C, Gao L-L, etal. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N EnglI Med 2012;367:1519-28.
24. Ghosh S, Goldin E, Gordon FH,etal. Natalizumab for active Crohn's disease. N EnglJ Med 2003;348:24-32.
25. Feagan BG, Greenberg GR, Wild G, etal. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008;6:1370-7.
26. Feagan BG, Sandborn WJ, D'Flaens G, et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology 2013; 145:149-57.
27. Vermeire S, Ghosh S, Panes J, etal. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. Gut 2011;60:1068-75.
28. D'Flaens G, Vermeire S, Vogelsang H,etal. Central nervous system immune surveillance and circulating B7+ CD4 T cells under anti-madcam-1 antibody treatment for Crohn's disease: report of theTOSCA study. Gut 2017.